Smart Grid

TMCNet:  Research and Markets: Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis

[January 11, 2013]

Research and Markets: Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/s5tpn9/baricitinib) has announced the addition of GlobalData's new report "Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis" to their offering.

GlobalData has released its new PharmaPoint Drug Evaluation report, Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Story continues below ↓

Eli Lilly and Company and Incyte Corporation are jointly developing baricitinib, an oral JAK1 and 2 inhibitor, under a worldwide license and collaboration agreement in which Lilly has the licensing rights. Baricitinib prevents intracellular signaling of IL-6 and IL-23, thereby reducing inflammation. Formerly known as LY3009104 to Lilly and as INCB28050 to Incyte, baricitinib is currently in Phase IIb clinical trials to study patients with active RA on background MTX. This trial is located in nine countries including the US and India. In addition to RA, baricitinib is in Phase IIb trials for the treatment of moderate to severe plaque psoriasis.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Baricitinib including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Baricitinib for the top eight countries from 2011 to 2022.

- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia.

Key Topics Covered:

1 List of Tables and Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Baricitinib (formerly LY3009104/INCB28050)

9 Appendix

For more information visit http://www.researchandmarkets.com/research/s5tpn9/baricitinib

Source (News - Alert): GlobalData


[ Back To Smart Grid Home's Homepage ]




blog comments powered by Disqus